Intermediates Intelligence, Reimagined
The world’s most structured platform for pharmaceutical intermediates and Key Starting Materials (KSMs).
With global supplier visibility, regulatory context, and structured, searchable datasets, we empower you to trace, plan, and source — all API-free.
Every dataset is curated to focus solely on intermediates and KSMs relevant to pharma — no noise, no distractions.
Trace molecules from synthesis routes to verified sources, with clarity on grade, use, and production linkage.
Access active exporters, manufacturers, and trade movements across India, China, Europe, and beyond.
Navigate thousands of compounds through filters like synthesis stage, therapeutic linkage, and compound type.
Where available, see REACH, EDQM, CEP, or other regulatory tags mapped to intermediates and their suppliers.
Explore intermediates independently of APIs — focused on raw materials, process planning, and upstream decision-making.
Discover how intermediates and KSMs move through synthesis routes, suppliers, and global trade flows. We’ve mapped 500+ key intermediates to their respective APIs and maintain a live catalog of over 7,000 pharma-relevant intermediates.
Identify the exact intermediates used in known API synthesis routes—fully traceable and cross-linked.
Multi-step or final-step intermediates tied to complex formulations or niche therapeutic areas.
Optically pure intermediates and high-value KSMs required for targeted drug synthesis.
Intermediates with multiple downstream pathways, often used across various therapeutic classes.
KeyIntermediates supports every player in the pharmaceutical synthesis and sourcing ecosystem
Producers of critical synthesis materials monitoring global demand, pricing, and buyer markets.
Partners executing synthesis routes and sourcing intermediates with supplier and regulatory confidence.
Tracking KSM flows, monitoring trade trends, managing compliance, and mapping HS/CAS linkages.
Ensuring traceability, CDSCO/EDQM/USDMF documentation, and synthesis material audit-readiness.
Vendors of synthesis inputs needing downstream visibility and buyer targeting by therapeutic relevance.
Evaluating suppliers, purity, costs, and risk for intermediates and material-specific sourcing decisions.
Selecting optimal intermediates and variants for stability, yield, and formulation compatibility.
Producers of critical synthesis materials monitoring global demand, pricing, and buyer markets.
Partners executing synthesis routes and sourcing intermediates with supplier and regulatory confidence.